Healthy Skepticism Library item: 6582

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Hoechst to discontinue Baralgin (dipyrone/pitofenone/fenpiverinium)
MaLAM International News 1995 May; 13:(5):2

Abstract:

Hoechst has decided to discontinue Baralgin. Hoechst provided MaLAM with a meta-analysis on the use of dipyrone to treat colicky pain but the methodology used to perform the meta-analysis was not described. There are safer alternatives to dipyrone

Keywords:
*analysis/Philippines/developing countries/Hoechst/dipyrone/Baralgin/company responses/quality of information/ safety & risk information/MaLAM/Medical Lobby for Appropriate Marketing/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/REGULATION, CODES, GUIDELINES: FEEDBACK TO COMPANIES